Contact Information: For further information contact: Fern Lazar David Carey Lazar Partners Ltd. 1-(866) GIVEN-IR
Given Imaging to Host Fourth Quarter and Full Year 2007 Financial Results Conference Calls
| Source: Given Imaging
YOQNEAM, ISRAEL--(Marketwire - January 24, 2008) - Given Imaging (NASDAQ : GIVN ), the global
leader in capsule endoscopy, today announced that the company will host
conference calls on Thursday, February 21 to discuss fourth quarter and
full year 2007 financial results. The company plans to release results
following the close of trading on Wednesday, February 20.
The company will host a conference call in English at 9:00am ET on
Thursday, February 21. To participate in this teleconference, please dial
(888) 213-3754 fifteen minutes before the conference is scheduled to
begin. Callers outside of the U.S. should dial (913) 312-0940. The call
will also be webcast live at www.givenimaging.com. A replay of the call
will be available for two weeks on the company's website, or until March 5,
2008 by dialing (888) 203-1112. Callers outside of the U.S. should dial
(719) 457-0820. The replay participant code is 4788458.
A separate conference call in Hebrew will take place on February 21 at
2:00pm Israel time, 7am ET. To access this call, please dial +972 3
9180609 ten minutes before the conference is scheduled to begin. A replay
of the call will be available from February 24 until February 26 by dialing
+972 3 9255948.
About Given Imaging Ltd.
Given Imaging is redefining gastrointestinal diagnosis by developing,
producing and marketing innovative, patient-friendly products for detecting
gastrointestinal disorders. The company's technology platform is the
PillCam® Platform, featuring the PillCam video capsule, a disposable,
miniature video camera contained in a capsule, which is ingested by the
patient, a sensor array, data recorder and RAPID® software. Given Imaging
has a number of available capsules: the PillCam SB video capsule to
visualize the entire small intestine which is currently marketed in the
United States and in more than 60 other countries; the PillCam ESO video
capsule to visualize the esophagus; the Agile™ patency capsule to
determine the free passage of the PillCam capsule in the GI tract and the
PillCam COLON video capsule to visualize the colon that has been cleared
for marketing in the European Union, and is pending clearance with the
United States Food and Drug Administration. More than 600,000 patients
worldwide have benefited from the PillCam capsule endoscopy procedure.
Given Imaging's headquarters, manufacturing and R&D facilities are located
in Yoqneam, Israel. It has operating subsidiary companies in the United
States, Germany, France, Japan and Australia. For more information, visit
http://www.givenimaging.com.
This press release contains forward-looking statements within the meaning
of the "safe harbor" provisions of the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements include, but are not
limited to, projections about our business and our future revenues,
expenses and profitability. Forward-looking statements may be, but are not
necessarily, identified by the use of forward-looking terminology such as
"may," "anticipates," "estimates," "expects," "intends," "plans,"
"believes," and words and terms of similar substance. Forward-looking
statements involve known and unknown risks, uncertainties and other factors
which may cause the actual events, results, performance, circumstances or
achievements of the Company to be materially different from any future
events, results, performance, circumstances or achievements expressed or
implied by such forward-looking statements. Factors that could cause actual
events, results, performance, circumstances or achievements to differ from
such forward-looking statements include, but are not limited to, the
following: (1) satisfactory results of clinical trials with PillCam Colon
(2) our ability to receive regulatory clearance or approval to market our
products or changes in regulatory environment, (3) our success in
implementing our sales, marketing and manufacturing plans, (4) protection
and validity of patents and other intellectual property rights, (5) the
impact of currency exchange rates, (6) the effect of competition by other
companies, (7) the outcome of future litigation, including patent
litigation with Olympus Corporation, (8) the reimbursement policies for our
product from healthcare payors, (9) quarterly variations in operating
results, (10) the possibility of armed conflict or civil or military unrest
in Israel, and (11) other risks and factors disclosed in our filings with
the U.S. Securities and Exchange Commission, including, but not limited to,
risks and factors identified under such headings as "Risk Factors,"
"Cautionary Language Regarding Forward-Looking Statements" and "Operating
Results and Financial Review and Prospects" in the Company's Annual Report
on Form 20-F for the year ended December 31, 2006. You are cautioned not to
place undue reliance on these forward-looking statements, which speak only
as of the date of this press release. Except for the Company's ongoing
obligations to disclose material information under the applicable
securities laws, it undertakes no obligation to release publicly any
revisions to any forward-looking statements, to report events or to report
the occurrence of unanticipated events.